PLYMOUTH, Mich.--(BUSINESS WIRE)--Esperion Therapeutics, Inc. (Nasdaq: ESPR), a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia, today announced the appointment of Mark E. McGovern, M.D., FACC, FACP, as a Director. Dr. McGovern will serve as a Class I director with a term of office expiring at the 2014 annual meeting of stockholders.
Help employers find you! Check out all the jobs and post your resume.
